Alk Abello A/S: * Stated on Tuesday MSD (called Merck in the United States and Canada) had actually informed
ALK of its strategies to end their collaboration arrangement * Stated all rights to GRASTEK, RAGWITEK and investigational home allergen SLIT-tablets for
U.S.A, Canada and Mexico to revert to ALK at no fee following six- month shift duration * Ongoing registration procedures for investigational HDM SLIT-tablet will continue
* North America stays major company opportunity and ALK will now undertake full strategic
analysis before deciding on modified method * Deal has no effect on ALK’s full-year outlook for 2016
* Acting CEO and Chairman Steen Riisgaard said: “The timing of this relocation is unexpected”
Source text: bit.ly/ 2avKbQ0 More business coverage: (Gdynia Newsroom).